Tim Wright, Editor, Contract Pharma01.21.21
Piramal Pharma Limited’s Pharma Solutions business, a contract development and manufacturing organization (CDMO), has entered an agreement to provide Theratechnologies with GMP manufacturing of sterile fill/finish drug product to support their developmental product as it enters into a first-in-humans clinical study.
The clinical material is being produced at the Piramal Pharma Solutions (PPS) manufacturing site in Lexington, KY, which is recognized globally for its expertise in sterile fill/finish services. It will be used in a Phase I trial for TH1902, Theratechnologies’ lead peptide-drug conjugate (PDC) (docetaxel conjugate). The Phase I trial design includes a dose escalation study to evaluate the safety, pharmacokinetics, maximum tolerated dose (MTD) and preliminary anti-tumor activity of TH1902 administered once every three weeks in patients with advanced solid tumors refractory to available anti-cancer therapies.
“Our Lexington team went the extra mile to provide solutions to ensure timely formulation development and production of the material,” said Peter DeYoung, chief executive officer, Piramal Pharma Solutions. “It’s yet another example of how we are focused on working with our customers to reduce the burden of disease on patients.”
The clinical material is being produced at the Piramal Pharma Solutions (PPS) manufacturing site in Lexington, KY, which is recognized globally for its expertise in sterile fill/finish services. It will be used in a Phase I trial for TH1902, Theratechnologies’ lead peptide-drug conjugate (PDC) (docetaxel conjugate). The Phase I trial design includes a dose escalation study to evaluate the safety, pharmacokinetics, maximum tolerated dose (MTD) and preliminary anti-tumor activity of TH1902 administered once every three weeks in patients with advanced solid tumors refractory to available anti-cancer therapies.
“Our Lexington team went the extra mile to provide solutions to ensure timely formulation development and production of the material,” said Peter DeYoung, chief executive officer, Piramal Pharma Solutions. “It’s yet another example of how we are focused on working with our customers to reduce the burden of disease on patients.”
